US EditionUTR Therapeutics Inc Announces IND submission to the US FDA for a First-in-Human Clinical Trial of an mRNA destabilizing drug targeting c-MYC driven cancers
Summary by Financial Post
2 Articles
2 Articles
All
Left
1
Center
Right
1
Waterloo ChronicleReposted by 
Financial Post
Financial PostUTR Therapeutics Inc Announces IND submission to the US FDA for a First-in-Human Clinical Trial of an mRNA destabilizing drug targeting c-MYC driven cancers
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- UTR Therapeutics Inc (UTRx Inc.), a drug development biotech company based in New York City, USA is pleased to announce a new milestone, the submission of an Investigational New Drug (IND) application…
·Waterloo, Canada
Read Full ArticleCoverage Details
Total News Sources2
Leaning Left1Leaning Right1Center0Last UpdatedBias Distribution50% Left, 50% Right
Bias Distribution
- 50% of the sources lean Left, 50% of the sources lean Right
50% Right
L 50%
R 50%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
